MARKET

NBSE

NBSE

NeuBase Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.87
-0.05
-0.72%
Closed 16:00 01/24 EST
OPEN
6.92
PREV CLOSE
6.92
HIGH
6.98
LOW
6.58
VOLUME
66.83K
TURNOVER
--
52 WEEK HIGH
8.30
52 WEEK LOW
1.730
MARKET CAP
117.32M
P/E (TTM)
-2.1079
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NBSE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NBSE News

  • NeuBase Therapeutics FY19 EPS $(0.45) Down From $(0.01) YoY
  • Benzinga.01/09 21:15
  • The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO
  • Benzinga.12/17/2019 12:56
  • The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
  • Benzinga.12/03/2019 12:59
  • NeuBase Therapeutics Wins The Scientists Top 10 Innovations of 2019 Award for its Janus Base Technology
  • GlobeNewswire.12/02/2019 13:00

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About NBSE

NeuBase Therapeutics, Inc., formerly Ohr Pharmaceutical, Inc. is a pharmaceutical company focused on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company's development pipeline consists of several programs and indications at various stages of development. Its product pipeline includes Squalamine Lactate Ophthalmic Solution 0.2% (Squalamine, also known as OHR-102), SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry- Age-Related Macular Degeneration (AMD) and Non-Ophthalmology Assets. OHR-102 is a therapeutic product that provides a non-invasive therapy to improve vision outcomes. The SKS sustained release technology is designed to develop drug formulations for ocular disease. In the Company's animal model for dry-AMD, mice are immunized with a carboxyethylpyrrole, which is bound to mouse serum albumin.
More

Webull offers Neubase Therapeutics Inc (NBSE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.